Analysis of the production efficiency and titration of various recombinant adeno-associated viruses

Young Ran Nam, Sung Jin Kim, Boyoung Lee, JinWoo Chang, Chul Hyen Joo, Yoo Kyum Kim, Heuiran Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Recombinant adeno-associated virus type 2 (rAAV2) viral vector, a non-pathogenic human parvovirus, has recently emerged as a gene transfer vehicle for cancer gene therapy. To utilize rAAV2 properly and safely while carrying out preclinical and clinical studies, it is crucial to exactly titer the virus. We therefore compared biological infectious rAAV2 titers with physical titers of rAAV2 vectors encoding various transgenes with different sized viral genomes. Biological rAAV2 infectivity was assayed by measuring the number of virus particles able to transduce Hela cells using several detection methods, including X-gal staining and immunocytostaining. Physical titers of rAAV2 were determined using a commercially available rAAV2 particle-specific enzyme-linked immunosorbent assay. We found that total rAAV2 particle production was consistent within the limited size variations of the rAAV2 genome, regardless of the difference in transgenes. In contrast, the infectious titer of rAAV2 differed greatly, even for the same viruses, due to variation in the sensitivity of the relevant assays. Thus, the results suggest that both infectious virus titer and total virus particle should be precisely measured for rAAV2 vector utilized in each study.

Original languageEnglish
Pages (from-to)761-766
Number of pages6
JournalOncology Reports
Volume12
Issue number4
Publication statusPublished - 2004 Oct 1

Fingerprint

Dependovirus
Virion
Viral Load
Transgenes
Parvovirus
Viral Genome
Neoplasm Genes
HeLa Cells
Genetic Therapy
Enzyme-Linked Immunosorbent Assay
Genome
Staining and Labeling

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nam, Y. R., Kim, S. J., Lee, B., Chang, J., Joo, C. H., Kim, Y. K., & Lee, H. (2004). Analysis of the production efficiency and titration of various recombinant adeno-associated viruses. Oncology Reports, 12(4), 761-766.
Nam, Young Ran ; Kim, Sung Jin ; Lee, Boyoung ; Chang, JinWoo ; Joo, Chul Hyen ; Kim, Yoo Kyum ; Lee, Heuiran. / Analysis of the production efficiency and titration of various recombinant adeno-associated viruses. In: Oncology Reports. 2004 ; Vol. 12, No. 4. pp. 761-766.
@article{7d61d92f241549edaa0e0d980e34f1e1,
title = "Analysis of the production efficiency and titration of various recombinant adeno-associated viruses",
abstract = "Recombinant adeno-associated virus type 2 (rAAV2) viral vector, a non-pathogenic human parvovirus, has recently emerged as a gene transfer vehicle for cancer gene therapy. To utilize rAAV2 properly and safely while carrying out preclinical and clinical studies, it is crucial to exactly titer the virus. We therefore compared biological infectious rAAV2 titers with physical titers of rAAV2 vectors encoding various transgenes with different sized viral genomes. Biological rAAV2 infectivity was assayed by measuring the number of virus particles able to transduce Hela cells using several detection methods, including X-gal staining and immunocytostaining. Physical titers of rAAV2 were determined using a commercially available rAAV2 particle-specific enzyme-linked immunosorbent assay. We found that total rAAV2 particle production was consistent within the limited size variations of the rAAV2 genome, regardless of the difference in transgenes. In contrast, the infectious titer of rAAV2 differed greatly, even for the same viruses, due to variation in the sensitivity of the relevant assays. Thus, the results suggest that both infectious virus titer and total virus particle should be precisely measured for rAAV2 vector utilized in each study.",
author = "Nam, {Young Ran} and Kim, {Sung Jin} and Boyoung Lee and JinWoo Chang and Joo, {Chul Hyen} and Kim, {Yoo Kyum} and Heuiran Lee",
year = "2004",
month = "10",
day = "1",
language = "English",
volume = "12",
pages = "761--766",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

Nam, YR, Kim, SJ, Lee, B, Chang, J, Joo, CH, Kim, YK & Lee, H 2004, 'Analysis of the production efficiency and titration of various recombinant adeno-associated viruses', Oncology Reports, vol. 12, no. 4, pp. 761-766.

Analysis of the production efficiency and titration of various recombinant adeno-associated viruses. / Nam, Young Ran; Kim, Sung Jin; Lee, Boyoung; Chang, JinWoo; Joo, Chul Hyen; Kim, Yoo Kyum; Lee, Heuiran.

In: Oncology Reports, Vol. 12, No. 4, 01.10.2004, p. 761-766.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Analysis of the production efficiency and titration of various recombinant adeno-associated viruses

AU - Nam, Young Ran

AU - Kim, Sung Jin

AU - Lee, Boyoung

AU - Chang, JinWoo

AU - Joo, Chul Hyen

AU - Kim, Yoo Kyum

AU - Lee, Heuiran

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Recombinant adeno-associated virus type 2 (rAAV2) viral vector, a non-pathogenic human parvovirus, has recently emerged as a gene transfer vehicle for cancer gene therapy. To utilize rAAV2 properly and safely while carrying out preclinical and clinical studies, it is crucial to exactly titer the virus. We therefore compared biological infectious rAAV2 titers with physical titers of rAAV2 vectors encoding various transgenes with different sized viral genomes. Biological rAAV2 infectivity was assayed by measuring the number of virus particles able to transduce Hela cells using several detection methods, including X-gal staining and immunocytostaining. Physical titers of rAAV2 were determined using a commercially available rAAV2 particle-specific enzyme-linked immunosorbent assay. We found that total rAAV2 particle production was consistent within the limited size variations of the rAAV2 genome, regardless of the difference in transgenes. In contrast, the infectious titer of rAAV2 differed greatly, even for the same viruses, due to variation in the sensitivity of the relevant assays. Thus, the results suggest that both infectious virus titer and total virus particle should be precisely measured for rAAV2 vector utilized in each study.

AB - Recombinant adeno-associated virus type 2 (rAAV2) viral vector, a non-pathogenic human parvovirus, has recently emerged as a gene transfer vehicle for cancer gene therapy. To utilize rAAV2 properly and safely while carrying out preclinical and clinical studies, it is crucial to exactly titer the virus. We therefore compared biological infectious rAAV2 titers with physical titers of rAAV2 vectors encoding various transgenes with different sized viral genomes. Biological rAAV2 infectivity was assayed by measuring the number of virus particles able to transduce Hela cells using several detection methods, including X-gal staining and immunocytostaining. Physical titers of rAAV2 were determined using a commercially available rAAV2 particle-specific enzyme-linked immunosorbent assay. We found that total rAAV2 particle production was consistent within the limited size variations of the rAAV2 genome, regardless of the difference in transgenes. In contrast, the infectious titer of rAAV2 differed greatly, even for the same viruses, due to variation in the sensitivity of the relevant assays. Thus, the results suggest that both infectious virus titer and total virus particle should be precisely measured for rAAV2 vector utilized in each study.

UR - http://www.scopus.com/inward/record.url?scp=16644372329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644372329&partnerID=8YFLogxK

M3 - Article

C2 - 15375497

AN - SCOPUS:16644372329

VL - 12

SP - 761

EP - 766

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -